R&D Trends

Report: Global stem cell market to reach $118B by 2018

Wednesday, December 3, 2014 01:02 PM

The global stem cell market earned revenues of $40.01 billion in 2013 and is estimated to nearly triple to $117.66 billion in 2018 at a compound annual growth rate (CAGR) of 24.1%, according to a new analysis from Frost & Sullivan. The study covers human adult and embryonic stem cells. While North America is the market leader with more than half of the global stem cell market share, Asia-Pacific is expected to record the highest CAGR during the forecast period. In fact, the APAC stem cell market, which was valued at $5.6 billion in 2013, is projected to increase to $18.71 billion by 2018.

More... »


Seattle Children's launches $100M fundraising initiative to cure childhood cancer

Wednesday, December 3, 2014 01:01 PM

Seattle Children's Hospital and Research Foundation has launched a $100 million, multi-year fundraising initiative to support research that scientists believe has the ability to cure some types of childhood cancer in the next five to 10 years.

More... »


Edison Nation Medical, Mount Sinai Health System collaborate

Wednesday, December 3, 2014 12:59 PM

Edison Nation Medical, a marketplace for healthcare and medical device innovation headquartered in Charlotte, N.C., has partnered with Mount Sinai Health System, a New York-based integrated healthcare network providing medical care and medical research. Edison Nation Medical will work closely with Mount Sinai Innovation Partners (MSIP), Mount Sinai's technology development and commercialization group, to prioritize and bring to market medical device and consumer related healthcare inventions from the Mount Sinai community.

More... »

Zosano Pharma, Eli Lilly to develop osteoporosis treatment

Wednesday, December 3, 2014 12:58 PM

Zosano Pharma, based in Fremont, Calif., and Eli Lilly have entered into an exclusive agreement to develop ZP-PTH, Zosano's proprietary formulation of parathyroid hormone 1-34 (PTH) using Zosano's microneedle patch system for treating osteoporosis patients, globally. Zosano has completed a phase II study of ZP-PTH for the treatment of severe osteoporosis and plans to conduct phase III development.

More... »

GeNeuro, Servier partner for multiple sclerosis

Wednesday, December 3, 2014 12:57 PM

GeNeuro, a Switzerland-based developer of new therapies for neurology and autoimmune disorders, has entered into a strategic partnership with Servier, an independent French pharmaceutical company, to develop and market GNbAC1 in multiple sclerosis (MS). As the first drug addressing a causal factor of the disease, GNbAC1 has the potential to radically change the way MS patients are treated.

More... »

Evotec, Sanofi to collaborate

Wednesday, December 3, 2014 12:55 PM

Evotec has entered into exclusive negotiations with Sanofi on a major multi-component strategic alliance over the next five years. The collaboration will comprise three major strategic initiatives all focused on improving innovation effectiveness in the drug discovery and preclinical development space.

More... »

Aeterna Zentaris, Sinopharm A-Think ink agreement

Monday, December 1, 2014 12:52 PM

Aeterna Zentaris, a specialty biopharmaceutical company based in Québec, and China-based Sinopharm A-Think Pharmaceuticals have signed of an exclusive license and technology transfer agreement for Aeterna Zentaris’ lead anti-cancer compound, zoptarelin doxorubicin, for the initial indication of endometrial cancer for the Chinese, Hong Kong and Macau markets (the territory). Zoptarelin doxorubicin, a novel synthetic peptide carrier linked to doxorubicin, currently is in a ZoptEC (zoptarelin doxorubicin in endometrial cancer) phase III trial in endometrial cancer.

More... »

Cancer Research U.K., AstraZeneca to collaborate

Monday, December 1, 2014 12:48 PM

AstraZeneca and Cancer Research U.K. have signed a memorandum of understanding through which Cancer Research U.K. drug discovery investigators would be given access to state-of-the-art drug discovery facilities at the new AZ MRC U.K. Center for Lead Discovery to be built in Cambridge.

More... »

Merck, NewLink Genetics collaborate on investigational Ebola vaccine

Wednesday, November 26, 2014 11:54 AM

Merck and Ames, Iowa-based NewLink Genetics have entered into an exclusive worldwide license agreement to research, develop, manufacture and distribute NewLink’s investigational rVSV-EBOV (Ebola) vaccine candidate.

More... »

Report: AML treatment market to witness modest growth by 2020

Wednesday, November 26, 2014 11:53 AM

The value of the global acute myeloid leukemia (AML) therapeutics market will increase moderately from $632.6 million in 2013 to $878.6 million by 2020, representing a Compound Annual Growth Rate (CAGR) of 4.8%, according to New York-based business intelligence provider GBI Research.

More... »

CenterWatch
CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs